Hemenway Trust Co LLC Grows Stock Holdings in Danaher Co. (NYSE:DHR)

Hemenway Trust Co LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 161,183 shares of the conglomerate’s stock after acquiring an additional 4,804 shares during the quarter. Danaher accounts for 3.0% of Hemenway Trust Co LLC’s holdings, making the stock its 13th biggest position. Hemenway Trust Co LLC’s holdings in Danaher were worth $37,000,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Howard Capital Management Group LLC grew its holdings in Danaher by 4.1% during the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after acquiring an additional 48 shares during the period. Integrated Wealth Concepts LLC increased its holdings in shares of Danaher by 5.2% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 8,201 shares of the conglomerate’s stock valued at $2,280,000 after purchasing an additional 408 shares in the last quarter. IHT Wealth Management LLC lifted its stake in shares of Danaher by 20.3% in the 3rd quarter. IHT Wealth Management LLC now owns 6,005 shares of the conglomerate’s stock valued at $1,666,000 after purchasing an additional 1,014 shares during the period. Texas Capital Bank Wealth Management Services Inc boosted its holdings in Danaher by 3.5% during the third quarter. Texas Capital Bank Wealth Management Services Inc now owns 33,260 shares of the conglomerate’s stock worth $9,247,000 after buying an additional 1,122 shares in the last quarter. Finally, Two Sigma Advisers LP purchased a new position in Danaher in the third quarter valued at $10,481,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

DHR stock opened at $181.42 on Friday. The business’s fifty day moving average price is $209.99 and its 200 day moving average price is $234.26. Danaher Co. has a 12-month low of $181.20 and a 12-month high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $129.66 billion, a PE ratio of 34.36, a P/E/G ratio of 2.66 and a beta of 0.86.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm earned $2.09 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.71%. The ex-dividend date is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio (DPR) is currently 24.24%.

Wall Street Analyst Weigh In

DHR has been the subject of several recent analyst reports. Guggenheim began coverage on Danaher in a research note on Thursday, December 19th. They issued a “buy” rating and a $275.00 price target for the company. Stifel Nicolaus upgraded Danaher from a “hold” rating to a “buy” rating and set a $260.00 price objective on the stock in a report on Friday, March 14th. Robert W. Baird reduced their target price on Danaher from $277.00 to $268.00 and set an “overweight” rating for the company in a report on Tuesday, January 28th. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research note on Friday, December 13th. Finally, Citigroup reduced their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.24.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.